Mendeley  

Zotero  

Hashemi R, Peymani M, Ghaedi K, Saffar H. Evaluation and Comparison of PBK and E2F7 Gene Expression Between Early and Advanced Stages of Colorectal Cancer. J Arak Uni Med Sci 2022; 25 (1) :14-27
URL: http://jams.arakmu.ac.ir/article-1-7024-en.html

Background and Aim PBK is a mitogen-activated protein kinase (MAPKK) among MEK1/2 and MEK7 and can phosphorylate P38, JNK, and ERK in many cellular functions. The E2F transcription factor family also belongs to a class of cellular regulators acting as oncogenes and tumor suppressors. This study aims to investigate the expression of PBK and E2F7 in the early stages of colorectal cancer (CRC) compared to advanced stages based on the experimental and TCGA (The Cancer Genome Atlas) database.
Methods & Materials A total of 32 tissue samples of patients with CRC with the approval of a pathobiologist were collected according to the examination and criteria reported from different stages. After RNA extraction and cDNA synthesis, the RT-qPCR technique was used to evaluate the expression of the desired genes in the study groups. A receiver operating characteristic (ROC) curve analysis was also used to determine the ability of each of the selected genes to differentiate the two populations: stage I+II and stage III+IV.
Ethical Considerations In all stages of this research, codes of ethics of research and publication were observed.
Results In this study, it was shown that the expression of PBK and E2F7 significantly increased in stage I+II samples compared to stage III+IV. These data were confirmed by laboratory results and information extracted from the TCGA database. Also, based on the area under curve obtained from the ROC curves, these two genes are significantly distinguishable between stage I+II and III+IV populations in CRC.
Conclusion According to the results of this study, PBK and E2F7 genes are good markers in the diagnosis of CRC.